Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes
| Autor: | C. Dalla Man, Claudio Cobelli, L. Xu, K. Thomas, P. P. Stein, R. Brazg |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Dipeptidyl Peptidase 4 Type 2 diabetes Dipeptidyl peptidase-4 inhibitor Placebo Gastroenterology Sitagliptin Phosphate chemistry.chemical_compound Endocrinology Internal medicine Insulin-Secreting Cells Internal Medicine medicine Humans Hypoglycemic Agents Protease Inhibitors Aged Dipeptidyl-Peptidase IV Inhibitors Cross-Over Studies business.industry Middle Aged Triazoles medicine.disease Metformin Fructosamine Treatment Outcome chemistry Diabetes Mellitus Type 2 Sitagliptin Pyrazines Female business medicine.drug Blood sampling |
| Popis: | AIM The aim of this study was to assess the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on 24-h glucose control when added to the regimen of patients with type 2 diabetes who had inadequate glycaemic control on metformin therapy. METHODS In a double-blind, randomized, placebo-controlled, two-period crossover study, patients with type 2 diabetes with inadequate glycaemic control on metformin monotherapy (i.e. on a stable dose of > or = 1500 mg/day for > or = 6 weeks prior to the screening visit and an haemoglobin A(1c) (HbA(1c)) > or = 6.5% and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|